Korean, Foreign Pharms Call For ‘Reasonable’ Drug Price System
This article was originally published in PharmAsia News
South Korean and foreign pharma firms have jointly urged the Korean government to postpone a planned drug price cut by one year in an effort to overcome the impact of the MERS outbreak, and have promised to cooperate to propose a balanced new drug pricing system as well as to recommend steps to promote better R&D in the sector.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.